MAPT and Alzheimer disease: Interestingly, Subtype 3 emerged as an outlier with an atypical A+/T− CSF biomarker profile, characterized by low tau levels despite elevated neurofilament, enrichment in AAs and men, and distinct proteomic signatures that challenge conventional AD diagnostic classification.